DK1175904T3 - Alendronat til anvendelse til behandling af osteoporose - Google Patents

Alendronat til anvendelse til behandling af osteoporose

Info

Publication number
DK1175904T3
DK1175904T3 DK01201913T DK01201913T DK1175904T3 DK 1175904 T3 DK1175904 T3 DK 1175904T3 DK 01201913 T DK01201913 T DK 01201913T DK 01201913 T DK01201913 T DK 01201913T DK 1175904 T3 DK1175904 T3 DK 1175904T3
Authority
DK
Denmark
Prior art keywords
disclosed
alendronate
osteoporosis
treatment
methods
Prior art date
Application number
DK01201913T
Other languages
Danish (da)
English (en)
Inventor
Anastasia G Daifotis
John A Yates
Arthur C Ii Santora
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1175904(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DK1175904T3 publication Critical patent/DK1175904T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
DK01201913T 1997-07-22 1998-07-17 Alendronat til anvendelse til behandling af osteoporose DK1175904T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption
PCT/US1998/014796 WO1999004773A2 (en) 1997-07-22 1998-07-17 Method for inhibiting bone resorption

Publications (1)

Publication Number Publication Date
DK1175904T3 true DK1175904T3 (da) 2007-05-07

Family

ID=27451690

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01201913T DK1175904T3 (da) 1997-07-22 1998-07-17 Alendronat til anvendelse til behandling af osteoporose
DK98935752T DK0998292T3 (da) 1997-07-22 1998-07-17 Fremgangsmåde til inhibering af knogleresorption

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98935752T DK0998292T3 (da) 1997-07-22 1998-07-17 Fremgangsmåde til inhibering af knogleresorption

Country Status (31)

Country Link
EP (5) EP1175904B8 (nl)
JP (2) JP3479780B2 (nl)
KR (3) KR20030097611A (nl)
CN (3) CN1299689C (nl)
AT (2) ATE209037T1 (nl)
AU (1) AU8493698A (nl)
BG (1) BG66282B1 (nl)
BR (1) BR9810779A (nl)
CA (1) CA2294595C (nl)
CY (2) CY1107535T1 (nl)
DE (6) DE69837450T2 (nl)
DK (2) DK1175904T3 (nl)
EA (1) EA004544B2 (nl)
EE (1) EE05603B1 (nl)
ES (3) ES2253136T1 (nl)
HK (5) HK1024166A1 (nl)
ID (1) ID24096A (nl)
IL (1) IL133535A0 (nl)
IS (3) IS5315A (nl)
LU (2) LU91222I2 (nl)
NL (2) NL300223I1 (nl)
NO (1) NO20000323L (nl)
NZ (1) NZ501807A (nl)
PL (1) PL195272B1 (nl)
PT (2) PT1175904E (nl)
SG (2) SG109478A1 (nl)
SI (1) SI0998292T1 (nl)
SK (1) SK932000A3 (nl)
TR (1) TR200000145T2 (nl)
UY (1) UY25950A1 (nl)
WO (1) WO1999004773A2 (nl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW476649B (en) 1998-12-25 2002-02-21 Yamanouchi Pharma Co Ltd Pharmaceutical composition for treating bone disease of multiple myeloma
DE60019580T2 (de) * 1999-05-21 2006-03-09 Novartis Ag Verwendung von biphosphonsäuren zur behandlung von angiogenese
US6670343B1 (en) * 1999-07-19 2003-12-30 Toray Industries, Inc. Drugs for periodontal disease
AU2270101A (en) * 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
US6978894B2 (en) 1999-12-20 2005-12-27 Merck & Co., Inc. Blister package for pharmaceutical treatment card
EP1267890A2 (en) * 2000-04-07 2003-01-02 The Board of Regents of The University of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
JP4722375B2 (ja) 2000-06-20 2011-07-13 ノバルティス アーゲー ビホスホネートの投与法
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
CA2444718A1 (en) * 2001-05-02 2002-11-14 Novartis Ag Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis
KR20060058151A (ko) * 2002-05-10 2006-05-29 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
MXPA06003063A (es) * 2003-09-19 2006-05-31 Pfizer Prod Inc Composiciones farmaceuticas y metodos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina- d y un bisfosfonato.
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
JP2009508834A (ja) * 2005-09-16 2009-03-05 セラマイン リミテッド ビスホスホネート製剤
EP2648702B1 (en) * 2010-12-06 2019-03-06 Effrx Pharmaceuticals SA Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
DK0521388T3 (da) * 1991-07-01 1995-09-11 Gergely Gerhard Fremgangsmåde til fremstilling af et farmaceutisk præparat med mindst to forskellige aktivstoffer samt anvendelsen af et sådant præparat
HU227530B1 (en) * 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
ES2111163T3 (es) * 1992-06-30 1998-03-01 Procter & Gamble Pharma Uso de fosfonatos para el tratamiento de la osteoporosis.
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
CA2221416A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
DE69726879T2 (de) * 1996-05-17 2004-10-14 Merck & Co., Inc. Biphosphonat-formulierung mit brausewirkung

Also Published As

Publication number Publication date
DE122007000063I1 (de) 2007-12-20
DE01201913T1 (de) 2007-02-08
NZ501807A (en) 2003-02-28
EP1175904A2 (en) 2002-01-30
NL300292I1 (nl) 2007-11-01
EA200000151A1 (ru) 2000-10-30
WO1999004773A2 (en) 1999-02-04
ES2269014T1 (es) 2007-04-01
LU91364I2 (fr) 2007-11-12
JP2002502433A (ja) 2002-01-22
JP3479780B2 (ja) 2003-12-15
EP1175903A2 (en) 2002-01-30
ID24096A (id) 2000-07-06
DE69803291D1 (de) 2002-02-21
WO1999004773A3 (en) 1999-04-15
WO1999004773A9 (en) 1999-10-28
CY2007022I1 (el) 2012-01-25
PL195272B1 (pl) 2007-08-31
EP1175904B8 (en) 2007-05-09
KR20010022110A (ko) 2001-03-15
HK1024166A1 (en) 2000-10-05
EP1175904A3 (en) 2002-12-18
EE05603B1 (et) 2012-12-17
BG104093A (en) 2000-10-31
KR20030097611A (ko) 2003-12-31
ES2253136T1 (es) 2006-06-01
UY25950A1 (es) 2000-09-29
IS7230A (is) 2004-04-21
DE122006000009I1 (de) 2006-06-14
PL338635A1 (en) 2000-11-06
EP1151752A3 (en) 2002-12-18
CN1602880A (zh) 2005-04-06
NL300223I1 (nl) 2006-04-03
JP2005068010A (ja) 2005-03-17
DE01201911T1 (de) 2007-10-18
CN1166365C (zh) 2004-09-15
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
ES2269014T3 (es) 2007-05-01
CA2294595C (en) 2001-08-21
CY1107535T1 (el) 2012-01-25
EP1175904B1 (en) 2007-03-28
ATE209037T1 (de) 2001-12-15
HK1042232A1 (zh) 2002-08-09
DE69803291T2 (de) 2002-08-08
DK0998292T3 (da) 2002-05-13
EE200000040A (et) 2000-10-16
PT1175904E (pt) 2007-04-30
EP0998292B1 (en) 2001-11-21
KR100391732B1 (ko) 2003-07-16
AU8493698A (en) 1999-02-16
DE69837450D1 (de) 2007-05-10
LU91222I2 (fr) 2006-04-18
EP1175903A3 (en) 2002-12-18
ATE357921T1 (de) 2007-04-15
EA004544B2 (ru) 2006-12-29
SG109478A1 (en) 2005-03-30
NO20000323L (no) 2000-03-20
EP1151752A2 (en) 2001-11-07
SK932000A3 (en) 2000-09-12
HK1040494A1 (zh) 2002-06-14
EP1132088A3 (en) 2002-04-24
CN1602879A (zh) 2005-04-06
DE69837450T2 (de) 2007-08-23
ES2164447T3 (es) 2002-02-16
CY2007022I2 (el) 2012-01-25
PT998292E (pt) 2002-04-29
IS7231A (is) 2004-04-21
HK1040495A1 (zh) 2002-06-14
EP1132088A2 (en) 2001-09-12
CN1265035A (zh) 2000-08-30
CA2294595A1 (en) 1999-02-04
BG66282B1 (bg) 2013-01-31
CN1299689C (zh) 2007-02-14
EP0998292A2 (en) 2000-05-10
IL133535A0 (en) 2001-04-30
EA004544B1 (ru) 2004-06-24
HK1042230A1 (zh) 2002-08-09
KR20030097610A (ko) 2003-12-31
IS5315A (is) 1999-12-21
SI0998292T1 (en) 2002-04-30
BR9810779A (pt) 2000-07-25
TR200000145T2 (tr) 2000-05-22

Similar Documents

Publication Publication Date Title
LU91364I2 (fr) Alendronate de sodium /colécalciférol
NZ545804A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
DE69905488D1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
YU1800A (sh) Upotreba bisfosfonata za proizvodnju leka za inhibiranje resorpcije kostiju
PE120399A1 (es) Composiciones que inhiben la resorcion osea